Child (3-12)
Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment-1 Study (MISSION-1)
Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment-1 Study (MISSION-1) will evaluate a six-month treatment of a medicine called tofacitinib to see if it can improve the health of individuals with Down syndrome.
Principal investigator
Joaquín Espinosa, PhD
Location
Denver, CO
Age range
6 to 22 years old
Exploring Quality of Life in Children With Down Syndrome After Leukemia
This study explores how children with Down syndrome in remission from leukemia and their families experience survivorship, focusing on their daily lives, support systems and strengths and skills gained through their experience.
Principal investigator
Karla Ausderau, PhD
Location
Virtual or Multiple locations within United States
Age range
5 to 21 years old
Down Syndrome Health Measure (DSHM) Survey
The Down Syndrome Health Measure (DSHM) is a new, short survey that was created specifically with people with Down syndrome in mind, and asks questions about aspects of overall health. Now that this final measure is available, we’re interested in collecting feedback on the survey from caregivers of individuals with Down syndrome age 0 to 21.
Principal investigator
Stephanie Santoro, MD
Location
Virtual
Age range
0 to 21 years old
Pagination
- Page 1
- Next page